Nervonik is developing a next-generation peripheral nerve stimulation platform that combines electrical stimulation with advanced sensing to enable more precise, personalized neuromodulation therapies. Its implantable leads have demonstrated the ability to record evoked compound action potentials (ECAPs) and other physiological biomarkers. The company is advancing clinical programs and preparing for commercialization of its PNS system. Recent financing will fund further development of its proprietary sensing capabilities and support commercialization activities. Nervonik is headquartered in Los Angeles, California.

Total raised

$66M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2026